develop two tests that detect
early multiple sclerosis
and predict its evolution
Two new test developed by Dr. Luisa María Villar, head of the Section of Immunochemistry of Hospital Ramón y Cajal Madrid allow early detection of multiple sclerosis (MS) and predict which patients develop more severe forms of this disease, may well choose the best treatment.
Villar has given Thursday at the Ramón y Cajal the theoretical-practical 'Biomarkers in cerebrospinal fluid', which along Cermak neurologist Carlos Alvarez, coordinator of the EM Unit of the hospital, explained these new techniques to 65 national experts from several hospitals.
One such test is the test of oligoclonal bands of immunoglobulins G (IgG) in cerebrospinal fluid, which can identify patients with early MS symptoms that may develop the disease. This test was a previous version, even commercially, that Villar has perfected to make it more responsive and thus more reliable results.
"There were oligoclonal IgG bands in the early diagnosis of MS, but were of low sensitivity, making this test requiring highly specialized laboratories and cause actual results to differ depending on who practiced" , explained the expert to Europa Press.
"Now this test is more sensitive and allows a more reliable early diagnosis, which means that can slow the progression of disability in these patients, who tend to be young with many years of illness ahead, "he says.
" It's important to stop as soon as neurodegeneration, because there is no treatment to reverse this damage and should be treated with new therapies in the early stages, when even the patient suffers no deficit, "he added.
The second test, created entirely by Dr. Villar, is the test of oligoclonal bands inmonuglobulina M (IgM). Lets find out, in patients with early symptoms of MS, which have a higher risk of developing this disease in its severest form. So eligible specialists in these cases, early treatments or stronger.
explains the expert, M is a protein inmonuglobulina difficult to manipulate in the laboratory. To facilitate their study, it occurred "break it down into more manageable subunits without altering its characteristics," a work that began at the Institute of Neurology in London and ended in the Ramón y Cajal, which successfully tested this method on their patients. "This allowed us to identify these patients and to treat them better," he concludes.
Villar has given Thursday at the Ramón y Cajal the theoretical-practical 'Biomarkers in cerebrospinal fluid', which along Cermak neurologist Carlos Alvarez, coordinator of the EM Unit of the hospital, explained these new techniques to 65 national experts from several hospitals.
One such test is the test of oligoclonal bands of immunoglobulins G (IgG) in cerebrospinal fluid, which can identify patients with early MS symptoms that may develop the disease. This test was a previous version, even commercially, that Villar has perfected to make it more responsive and thus more reliable results.
"There were oligoclonal IgG bands in the early diagnosis of MS, but were of low sensitivity, making this test requiring highly specialized laboratories and cause actual results to differ depending on who practiced" , explained the expert to Europa Press.
"Now this test is more sensitive and allows a more reliable early diagnosis, which means that can slow the progression of disability in these patients, who tend to be young with many years of illness ahead, "he says.
" It's important to stop as soon as neurodegeneration, because there is no treatment to reverse this damage and should be treated with new therapies in the early stages, when even the patient suffers no deficit, "he added.
The second test, created entirely by Dr. Villar, is the test of oligoclonal bands inmonuglobulina M (IgM). Lets find out, in patients with early symptoms of MS, which have a higher risk of developing this disease in its severest form. So eligible specialists in these cases, early treatments or stronger.
explains the expert, M is a protein inmonuglobulina difficult to manipulate in the laboratory. To facilitate their study, it occurred "break it down into more manageable subunits without altering its characteristics," a work that began at the Institute of Neurology in London and ended in the Ramón y Cajal, which successfully tested this method on their patients. "This allowed us to identify these patients and to treat them better," he concludes.
0 comments:
Post a Comment